nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—ABCC5—Cisplatin—peripheral nervous system neoplasm	0.381	1	CbGbCtD
Alprostadil—PTGIR—Endothelin Pathways—COX2—peripheral nervous system neoplasm	0.00494	0.0642	CbGpPWpGaD
Alprostadil—PTGIR—Prostacyclin signalling through prostacyclin receptor—GNAS—peripheral nervous system neoplasm	0.00327	0.0425	CbGpPWpGaD
Alprostadil—PTGIR—Endothelin Pathways—GNAS—peripheral nervous system neoplasm	0.0021	0.0273	CbGpPWpGaD
Alprostadil—ABCC4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.00209	0.0272	CbGpPWpGaD
Alprostadil—PTGER2—G alpha (s) signalling events—VIP—peripheral nervous system neoplasm	0.00208	0.0271	CbGpPWpGaD
Alprostadil—ABCC5—ABC-family proteins mediated transport—ABCB1—peripheral nervous system neoplasm	0.00165	0.0215	CbGpPWpGaD
Alprostadil—ABCC5—Defective B3GAT3 causes JDSSDHD—GNS—peripheral nervous system neoplasm	0.00165	0.0214	CbGpPWpGaD
Alprostadil—PTGIR—G alpha (s) signalling events—VIP—peripheral nervous system neoplasm	0.00141	0.0183	CbGpPWpGaD
Alprostadil—PTGER1—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.00134	0.0174	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00131	0.017	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.00119	0.0155	CbGpPWpGaD
Alprostadil—ABCC4—Ectoderm Differentiation—NF2—peripheral nervous system neoplasm	0.00119	0.0155	CbGpPWpGaD
Alprostadil—ABCC4—ABC-family proteins mediated transport—ABCB1—peripheral nervous system neoplasm	0.00115	0.0149	CbGpPWpGaD
Alprostadil—PTGER2—G alpha (s) signalling events—GNAS—peripheral nervous system neoplasm	0.00108	0.014	CbGpPWpGaD
Alprostadil—PTGIR—Platelet homeostasis—GNAS—peripheral nervous system neoplasm	0.00106	0.0137	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000997	0.013	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000956	0.0124	CbGpPWpGaD
Alprostadil—ABCC5—Carbohydrate metabolism—GNS—peripheral nervous system neoplasm	0.000885	0.0115	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000885	0.0115	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000885	0.0115	CbGpPWpGaD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.00082	0.0107	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000788	0.0102	CbGpPWpGaD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000778	0.0101	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000747	0.00971	CbGpPWpGaD
Alprostadil—PTGIR—Platelet homeostasis—PTPN11—peripheral nervous system neoplasm	0.000734	0.00954	CbGpPWpGaD
Alprostadil—PTGIR—G alpha (s) signalling events—GNAS—peripheral nervous system neoplasm	0.000729	0.00948	CbGpPWpGaD
Alprostadil—ABCC4—Platelet degranulation—KNG1—peripheral nervous system neoplasm	0.000706	0.00917	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000684	0.00889	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000674	0.00876	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000674	0.00876	CbGpPWpGaD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—KNG1—peripheral nervous system neoplasm	0.000672	0.00874	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000646	0.00839	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000646	0.00839	CbGpPWpGaD
Alprostadil—PTGER1—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.0006	0.0078	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000588	0.00765	CbGpPWpGaD
Alprostadil—ABCC4—Platelet degranulation—HGF—peripheral nervous system neoplasm	0.000588	0.00764	CbGpPWpGaD
Alprostadil—ABCC5—Fluoropyrimidine Activity—TP53—peripheral nervous system neoplasm	0.000578	0.00751	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000564	0.00733	CbGpPWpGaD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—HGF—peripheral nervous system neoplasm	0.00056	0.00728	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000537	0.00698	CbGpPWpGaD
Alprostadil—ABCC5—Carbohydrate metabolism—ENO2—peripheral nervous system neoplasm	0.000536	0.00697	CbGpPWpGaD
Alprostadil—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.000525	0.000969	CcSEcCtD
Alprostadil—Abdominal pain—Tretinoin—peripheral nervous system neoplasm	0.000525	0.000969	CcSEcCtD
Alprostadil—Abdominal pain—Isotretinoin—peripheral nervous system neoplasm	0.000525	0.000969	CcSEcCtD
Alprostadil—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.000525	0.000969	CcSEcCtD
Alprostadil—Cramps of lower extremities—Doxorubicin—peripheral nervous system neoplasm	0.000525	0.000969	CcSEcCtD
Alprostadil—ABCC5—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000524	0.00681	CbGpPWpGaD
Alprostadil—Discomfort—Alitretinoin—peripheral nervous system neoplasm	0.000519	0.000958	CcSEcCtD
Alprostadil—Ecchymosis—Doxorubicin—peripheral nervous system neoplasm	0.000516	0.000953	CcSEcCtD
Alprostadil—Diabetes mellitus—Epirubicin—peripheral nervous system neoplasm	0.000515	0.000951	CcSEcCtD
Alprostadil—Convulsion—Vincristine—peripheral nervous system neoplasm	0.000515	0.000951	CcSEcCtD
Alprostadil—Dry mouth—Alitretinoin—peripheral nervous system neoplasm	0.000514	0.000948	CcSEcCtD
Alprostadil—Flushing—Etoposide—peripheral nervous system neoplasm	0.000513	0.000948	CcSEcCtD
Alprostadil—Hypertension—Vincristine—peripheral nervous system neoplasm	0.000513	0.000947	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000512	0.00665	CbGpPWpGaD
Alprostadil—Muscle spasms—Cisplatin—peripheral nervous system neoplasm	0.000505	0.000933	CcSEcCtD
Alprostadil—Oedema—Alitretinoin—peripheral nervous system neoplasm	0.000503	0.000929	CcSEcCtD
Alprostadil—Infection—Alitretinoin—peripheral nervous system neoplasm	0.0005	0.000923	CcSEcCtD
Alprostadil—Abnormal vision—Doxorubicin—peripheral nervous system neoplasm	0.000498	0.00092	CcSEcCtD
Alprostadil—Sepsis—Doxorubicin—peripheral nervous system neoplasm	0.000496	0.000915	CcSEcCtD
Alprostadil—Shock—Alitretinoin—peripheral nervous system neoplasm	0.000495	0.000914	CcSEcCtD
Alprostadil—Cardiac failure congestive—Epirubicin—peripheral nervous system neoplasm	0.000494	0.000912	CcSEcCtD
Alprostadil—Thrombocytopenia—Alitretinoin—peripheral nervous system neoplasm	0.000493	0.00091	CcSEcCtD
Alprostadil—Tachycardia—Alitretinoin—peripheral nervous system neoplasm	0.000491	0.000907	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000491	0.00638	CbGpPWpGaD
Alprostadil—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.000489	0.000903	CcSEcCtD
Alprostadil—Hyperhidrosis—Alitretinoin—peripheral nervous system neoplasm	0.000487	0.000898	CcSEcCtD
Alprostadil—Anaemia—Cisplatin—peripheral nervous system neoplasm	0.000486	0.000897	CcSEcCtD
Alprostadil—Oedema—Vincristine—peripheral nervous system neoplasm	0.000485	0.000895	CcSEcCtD
Alprostadil—Infection—Vincristine—peripheral nervous system neoplasm	0.000482	0.00089	CcSEcCtD
Alprostadil—Asthenia—Topotecan—peripheral nervous system neoplasm	0.00048	0.000887	CcSEcCtD
Alprostadil—Diabetes mellitus—Doxorubicin—peripheral nervous system neoplasm	0.000477	0.00088	CcSEcCtD
Alprostadil—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000477	0.00088	CcSEcCtD
Alprostadil—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000477	0.00088	CcSEcCtD
Alprostadil—Thrombocytopenia—Vincristine—peripheral nervous system neoplasm	0.000475	0.000877	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000474	0.00616	CbGpPWpGaD
Alprostadil—Pruritus—Topotecan—peripheral nervous system neoplasm	0.000474	0.000875	CcSEcCtD
Alprostadil—Asthenia—Melphalan—peripheral nervous system neoplasm	0.00047	0.000868	CcSEcCtD
Alprostadil—Hypotension—Alitretinoin—peripheral nervous system neoplasm	0.00047	0.000868	CcSEcCtD
Alprostadil—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.00047	0.000868	CcSEcCtD
Alprostadil—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.00047	0.000868	CcSEcCtD
Alprostadil—Hyperhidrosis—Vincristine—peripheral nervous system neoplasm	0.000469	0.000866	CcSEcCtD
Alprostadil—Back pain—Etoposide—peripheral nervous system neoplasm	0.000466	0.00086	CcSEcCtD
Alprostadil—Pain—Dactinomycin—peripheral nervous system neoplasm	0.000464	0.000857	CcSEcCtD
Alprostadil—Pruritus—Melphalan—peripheral nervous system neoplasm	0.000464	0.000856	CcSEcCtD
Alprostadil—Muscle spasms—Etoposide—peripheral nervous system neoplasm	0.000463	0.000855	CcSEcCtD
Alprostadil—Hypoglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000459	0.000848	CcSEcCtD
Alprostadil—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.000458	0.000846	CcSEcCtD
Alprostadil—Lethargy—Epirubicin—peripheral nervous system neoplasm	0.000457	0.000844	CcSEcCtD
Alprostadil—Cardiac failure congestive—Doxorubicin—peripheral nervous system neoplasm	0.000457	0.000844	CcSEcCtD
Alprostadil—Convulsion—Cisplatin—peripheral nervous system neoplasm	0.000455	0.000841	CcSEcCtD
Alprostadil—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000454	0.000839	CcSEcCtD
Alprostadil—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000454	0.000839	CcSEcCtD
Alprostadil—Hypotension—Vincristine—peripheral nervous system neoplasm	0.000453	0.000837	CcSEcCtD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000451	0.00586	CbGpPWpGaD
Alprostadil—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000449	0.000828	CcSEcCtD
Alprostadil—Pain in extremity—Epirubicin—peripheral nervous system neoplasm	0.000448	0.000827	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000448	0.00582	CbGpPWpGaD
Alprostadil—Feeling abnormal—Dactinomycin—peripheral nervous system neoplasm	0.000447	0.000826	CcSEcCtD
Alprostadil—Anaemia—Etoposide—peripheral nervous system neoplasm	0.000445	0.000822	CcSEcCtD
Alprostadil—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.000443	0.000818	CcSEcCtD
Alprostadil—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000443	0.000817	CcSEcCtD
Alprostadil—Discomfort—Cisplatin—peripheral nervous system neoplasm	0.000442	0.000816	CcSEcCtD
Alprostadil—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000439	0.000811	CcSEcCtD
Alprostadil—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000439	0.000811	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000433	0.00563	CbGpPWpGaD
Alprostadil—ABCC5—Carbohydrate metabolism—SLC2A1—peripheral nervous system neoplasm	0.000432	0.00562	CbGpPWpGaD
Alprostadil—Pain—Alitretinoin—peripheral nervous system neoplasm	0.00043	0.000795	CcSEcCtD
Alprostadil—ABCC5—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.00043	0.00559	CbGpPWpGaD
Alprostadil—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000429	0.000792	CcSEcCtD
Alprostadil—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000429	0.000792	CcSEcCtD
Alprostadil—Oedema—Cisplatin—peripheral nervous system neoplasm	0.000429	0.000792	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000427	0.00555	CbGpPWpGaD
Alprostadil—Cardiac arrest—Epirubicin—peripheral nervous system neoplasm	0.000426	0.000787	CcSEcCtD
Alprostadil—Infection—Cisplatin—peripheral nervous system neoplasm	0.000426	0.000787	CcSEcCtD
Alprostadil—Hypoglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000425	0.000784	CcSEcCtD
Alprostadil—Loss of consciousness—Etoposide—peripheral nervous system neoplasm	0.000423	0.000781	CcSEcCtD
Alprostadil—Lethargy—Doxorubicin—peripheral nervous system neoplasm	0.000423	0.000781	CcSEcCtD
Alprostadil—Rash—Topotecan—peripheral nervous system neoplasm	0.000422	0.000779	CcSEcCtD
Alprostadil—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000422	0.000779	CcSEcCtD
Alprostadil—Cough—Etoposide—peripheral nervous system neoplasm	0.00042	0.000776	CcSEcCtD
Alprostadil—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	0.00042	0.000775	CcSEcCtD
Alprostadil—Blood creatinine increased—Epirubicin—peripheral nervous system neoplasm	0.00042	0.000775	CcSEcCtD
Alprostadil—Headache—Topotecan—peripheral nervous system neoplasm	0.000419	0.000774	CcSEcCtD
Alprostadil—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000419	0.000773	CcSEcCtD
Alprostadil—Rash—Tretinoin—peripheral nervous system neoplasm	0.000419	0.000773	CcSEcCtD
Alprostadil—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000419	0.000773	CcSEcCtD
Alprostadil—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000418	0.000772	CcSEcCtD
Alprostadil—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000418	0.000772	CcSEcCtD
Alprostadil—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000417	0.00077	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000417	0.00542	CbGpPWpGaD
Alprostadil—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000417	0.000769	CcSEcCtD
Alprostadil—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000416	0.000768	CcSEcCtD
Alprostadil—Headache—Tretinoin—peripheral nervous system neoplasm	0.000416	0.000768	CcSEcCtD
Alprostadil—Hypertension—Etoposide—peripheral nervous system neoplasm	0.000416	0.000767	CcSEcCtD
Alprostadil—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000415	0.000766	CcSEcCtD
Alprostadil—Pain—Vincristine—peripheral nervous system neoplasm	0.000415	0.000766	CcSEcCtD
Alprostadil—Pain in extremity—Doxorubicin—peripheral nervous system neoplasm	0.000415	0.000766	CcSEcCtD
Alprostadil—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000415	0.000765	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000414	0.00538	CbGpPWpGaD
Alprostadil—Rash—Melphalan—peripheral nervous system neoplasm	0.000413	0.000763	CcSEcCtD
Alprostadil—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000413	0.000762	CcSEcCtD
Alprostadil—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	0.000408	0.000753	CcSEcCtD
Alprostadil—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000405	0.000748	CcSEcCtD
Alprostadil—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000401	0.00074	CcSEcCtD
Alprostadil—ABCC4—Fluoropyrimidine Activity—TP53—peripheral nervous system neoplasm	0.0004	0.00521	CbGpPWpGaD
Alprostadil—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000398	0.000735	CcSEcCtD
Alprostadil—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000398	0.000735	CcSEcCtD
Alprostadil—Nausea—Topotecan—peripheral nervous system neoplasm	0.000398	0.000734	CcSEcCtD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000397	0.00517	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000397	0.00517	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000395	0.00514	CbGpPWpGaD
Alprostadil—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000395	0.000728	CcSEcCtD
Alprostadil—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000395	0.000728	CcSEcCtD
Alprostadil—Cardiac arrest—Doxorubicin—peripheral nervous system neoplasm	0.000394	0.000728	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000392	0.00509	CbGpPWpGaD
Alprostadil—Infection—Etoposide—peripheral nervous system neoplasm	0.00039	0.000721	CcSEcCtD
Alprostadil—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000389	0.000719	CcSEcCtD
Alprostadil—Nausea—Melphalan—peripheral nervous system neoplasm	0.000389	0.000719	CcSEcCtD
Alprostadil—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	0.000388	0.000717	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000388	0.00504	CbGpPWpGaD
Alprostadil—Influenza—Epirubicin—peripheral nervous system neoplasm	0.000387	0.000715	CcSEcCtD
Alprostadil—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000385	0.00071	CcSEcCtD
Alprostadil—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000383	0.000708	CcSEcCtD
Alprostadil—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000383	0.000708	CcSEcCtD
Alprostadil—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000383	0.000708	CcSEcCtD
Alprostadil—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000382	0.000705	CcSEcCtD
Alprostadil—PTGIR—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000381	0.00495	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000381	0.00495	CbGpPWpGaD
Alprostadil—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.00038	0.000701	CcSEcCtD
Alprostadil—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	0.000377	0.000697	CcSEcCtD
Alprostadil—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000372	0.000688	CcSEcCtD
Alprostadil—PTGIR—Thromboxane A2 receptor signaling—AKT1—peripheral nervous system neoplasm	0.000372	0.00483	CbGpPWpGaD
Alprostadil—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000371	0.000686	CcSEcCtD
Alprostadil—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000367	0.000678	CcSEcCtD
Alprostadil—Pain—Cisplatin—peripheral nervous system neoplasm	0.000367	0.000677	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000363	0.00472	CbGpPWpGaD
Alprostadil—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000361	0.000667	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.00036	0.000665	CcSEcCtD
Alprostadil—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000358	0.000662	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000358	0.00465	CbGpPWpGaD
Alprostadil—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000358	0.000661	CcSEcCtD
Alprostadil—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000356	0.000657	CcSEcCtD
Alprostadil—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000353	0.000652	CcSEcCtD
Alprostadil—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000349	0.000645	CcSEcCtD
Alprostadil—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000348	0.000642	CcSEcCtD
Alprostadil—PTGIR—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000346	0.00449	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000346	0.00449	CbGpPWpGaD
Alprostadil—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000345	0.000636	CcSEcCtD
Alprostadil—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000344	0.000636	CcSEcCtD
Alprostadil—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000342	0.000632	CcSEcCtD
Alprostadil—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000339	0.000627	CcSEcCtD
Alprostadil—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000339	0.000626	CcSEcCtD
Alprostadil—Pain—Etoposide—peripheral nervous system neoplasm	0.000336	0.00062	CcSEcCtD
Alprostadil—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000336	0.00062	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000335	0.00436	CbGpPWpGaD
Alprostadil—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000333	0.000615	CcSEcCtD
Alprostadil—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000333	0.000615	CcSEcCtD
Alprostadil—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000332	0.000613	CcSEcCtD
Alprostadil—PTGER1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000331	0.00431	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000331	0.00431	CbGpPWpGaD
Alprostadil—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000331	0.000611	CcSEcCtD
Alprostadil—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000329	0.000608	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000329	0.00428	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000326	0.00424	CbGpPWpGaD
Alprostadil—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000324	0.000598	CcSEcCtD
Alprostadil—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000324	0.000598	CcSEcCtD
Alprostadil—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000323	0.000597	CcSEcCtD
Alprostadil—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000322	0.000595	CcSEcCtD
Alprostadil—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000321	0.000592	CcSEcCtD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000318	0.00413	CbGpPWpGaD
Alprostadil—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000317	0.000586	CcSEcCtD
Alprostadil—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000317	0.000585	CcSEcCtD
Alprostadil—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000316	0.000583	CcSEcCtD
Alprostadil—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000315	0.000582	CcSEcCtD
Alprostadil—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000314	0.00058	CcSEcCtD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—KNG1—peripheral nervous system neoplasm	0.000313	0.00407	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000312	0.00406	CbGpPWpGaD
Alprostadil—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000312	0.000575	CcSEcCtD
Alprostadil—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000311	0.000574	CcSEcCtD
Alprostadil—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000311	0.000573	CcSEcCtD
Alprostadil—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000311	0.000573	CcSEcCtD
Alprostadil—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000311	0.000573	CcSEcCtD
Alprostadil—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.00031	0.000572	CcSEcCtD
Alprostadil—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000308	0.000569	CcSEcCtD
Alprostadil—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000308	0.000568	CcSEcCtD
Alprostadil—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000308	0.000568	CcSEcCtD
Alprostadil—Rash—Vincristine—peripheral nervous system neoplasm	0.000306	0.000565	CcSEcCtD
Alprostadil—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000306	0.000564	CcSEcCtD
Alprostadil—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000305	0.000562	CcSEcCtD
Alprostadil—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000304	0.000561	CcSEcCtD
Alprostadil—Headache—Vincristine—peripheral nervous system neoplasm	0.000304	0.000561	CcSEcCtD
Alprostadil—PTGER1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000303	0.00393	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000303	0.00393	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000302	0.00393	CbGpPWpGaD
Alprostadil—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.0003	0.000553	CcSEcCtD
Alprostadil—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000299	0.000552	CcSEcCtD
Alprostadil—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000299	0.000552	CcSEcCtD
Alprostadil—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000293	0.000542	CcSEcCtD
Alprostadil—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000292	0.000539	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—IFNB1—peripheral nervous system neoplasm	0.000292	0.0038	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.00029	0.00378	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.00029	0.00377	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000288	0.00375	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000288	0.00375	CbGpPWpGaD
Alprostadil—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000288	0.000532	CcSEcCtD
Alprostadil—Nausea—Vincristine—peripheral nervous system neoplasm	0.000288	0.000532	CcSEcCtD
Alprostadil—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000288	0.000531	CcSEcCtD
Alprostadil—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.000288	0.000531	CcSEcCtD
Alprostadil—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000287	0.00053	CcSEcCtD
Alprostadil—ABCC4—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000287	0.00373	CbGpPWpGaD
Alprostadil—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000285	0.000527	CcSEcCtD
Alprostadil—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000285	0.000526	CcSEcCtD
Alprostadil—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000282	0.00052	CcSEcCtD
Alprostadil—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000281	0.000519	CcSEcCtD
Alprostadil—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000278	0.000513	CcSEcCtD
Alprostadil—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000276	0.00051	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—KNG1—peripheral nervous system neoplasm	0.000271	0.00352	CbGpPWpGaD
Alprostadil—Rash—Cisplatin—peripheral nervous system neoplasm	0.00027	0.000499	CcSEcCtD
Alprostadil—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.00027	0.000499	CcSEcCtD
Alprostadil—Erythema—Epirubicin—peripheral nervous system neoplasm	0.00027	0.000498	CcSEcCtD
Alprostadil—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000269	0.000496	CcSEcCtD
Alprostadil—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000266	0.000491	CcSEcCtD
Alprostadil—PTGIR—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000265	0.00344	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000265	0.00344	CbGpPWpGaD
Alprostadil—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000262	0.000484	CcSEcCtD
Alprostadil—PTGER1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000262	0.00341	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000262	0.00341	CbGpPWpGaD
Alprostadil—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000261	0.000482	CcSEcCtD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	0.000261	0.00339	CbGpPWpGaD
Alprostadil—Dizziness—Etoposide—peripheral nervous system neoplasm	0.00026	0.00048	CcSEcCtD
Alprostadil—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000259	0.000479	CcSEcCtD
Alprostadil—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000255	0.00047	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000253	0.00329	CbGpPWpGaD
Alprostadil—ABCC5—Disease—GNS—peripheral nervous system neoplasm	0.000251	0.00326	CbGpPWpGaD
Alprostadil—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.00025	0.000461	CcSEcCtD
Alprostadil—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000249	0.00046	CcSEcCtD
Alprostadil—Rash—Etoposide—peripheral nervous system neoplasm	0.000248	0.000457	CcSEcCtD
Alprostadil—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000248	0.000457	CcSEcCtD
Alprostadil—Headache—Etoposide—peripheral nervous system neoplasm	0.000246	0.000454	CcSEcCtD
Alprostadil—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000243	0.000448	CcSEcCtD
Alprostadil—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000242	0.000447	CcSEcCtD
Alprostadil—PTGER1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000242	0.00314	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000242	0.00314	CbGpPWpGaD
Alprostadil—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000242	0.000446	CcSEcCtD
Alprostadil—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.00024	0.000443	CcSEcCtD
Alprostadil—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000237	0.000438	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—GNAS—peripheral nervous system neoplasm	0.000237	0.00308	CbGpPWpGaD
Alprostadil—Cough—Epirubicin—peripheral nervous system neoplasm	0.000235	0.000435	CcSEcCtD
Alprostadil—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000234	0.000432	CcSEcCtD
Alprostadil—Nausea—Etoposide—peripheral nervous system neoplasm	0.000233	0.000431	CcSEcCtD
Alprostadil—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000233	0.00043	CcSEcCtD
Alprostadil—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000231	0.000426	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.00023	0.00299	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000229	0.00298	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000229	0.00298	CbGpPWpGaD
Alprostadil—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000227	0.000419	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—HGF—peripheral nervous system neoplasm	0.000225	0.00293	CbGpPWpGaD
Alprostadil—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000225	0.000415	CcSEcCtD
Alprostadil—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000224	0.000413	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000221	0.00288	CbGpPWpGaD
Alprostadil—Oedema—Epirubicin—peripheral nervous system neoplasm	0.00022	0.000407	CcSEcCtD
Alprostadil—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000219	0.000405	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000219	0.00285	CbGpPWpGaD
Alprostadil—Infection—Epirubicin—peripheral nervous system neoplasm	0.000219	0.000404	CcSEcCtD
Alprostadil—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000218	0.000402	CcSEcCtD
Alprostadil—Shock—Epirubicin—peripheral nervous system neoplasm	0.000217	0.0004	CcSEcCtD
Alprostadil—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000216	0.000399	CcSEcCtD
Alprostadil—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000216	0.000398	CcSEcCtD
Alprostadil—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000216	0.000398	CcSEcCtD
Alprostadil—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000215	0.000397	CcSEcCtD
Alprostadil—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000214	0.000395	CcSEcCtD
Alprostadil—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000213	0.000393	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000211	0.00275	CbGpPWpGaD
Alprostadil—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.00021	0.000388	CcSEcCtD
Alprostadil—ABCC5—Metabolism—GNS—peripheral nervous system neoplasm	0.00021	0.00273	CbGpPWpGaD
Alprostadil—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000208	0.000384	CcSEcCtD
Alprostadil—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000206	0.00038	CcSEcCtD
Alprostadil—PTGIR—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000204	0.00265	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000204	0.00265	CbGpPWpGaD
Alprostadil—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000204	0.000376	CcSEcCtD
Alprostadil—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000202	0.000374	CcSEcCtD
Alprostadil—ABCC5—Metabolism—NME1—peripheral nervous system neoplasm	0.000201	0.00262	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000201	0.00261	CbGpPWpGaD
Alprostadil—Shock—Doxorubicin—peripheral nervous system neoplasm	0.0002	0.00037	CcSEcCtD
Alprostadil—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.0002	0.000368	CcSEcCtD
Alprostadil—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.000367	CcSEcCtD
Alprostadil—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000198	0.000365	CcSEcCtD
Alprostadil—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000197	0.000364	CcSEcCtD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	0.000196	0.00255	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000196	0.00254	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000196	0.00254	CbGpPWpGaD
Alprostadil—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000194	0.000358	CcSEcCtD
Alprostadil—ABCC5—Metabolism—COX2—peripheral nervous system neoplasm	0.000194	0.00252	CbGpPWpGaD
Alprostadil—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.00019	0.000352	CcSEcCtD
Alprostadil—Pain—Epirubicin—peripheral nervous system neoplasm	0.000188	0.000348	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000184	0.0024	CbGpPWpGaD
Alprostadil—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000181	0.000335	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000181	0.00235	CbGpPWpGaD
Alprostadil—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000179	0.000331	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000176	0.00229	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PPP3R1—peripheral nervous system neoplasm	0.000175	0.00228	CbGpPWpGaD
Alprostadil—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000174	0.000322	CcSEcCtD
Alprostadil—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000174	0.000321	CcSEcCtD
Alprostadil—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000174	0.000321	CcSEcCtD
Alprostadil—ABCC4—Hemostasis—IFNB1—peripheral nervous system neoplasm	0.000174	0.00226	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000173	0.00225	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000171	0.00222	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000171	0.00222	CbGpPWpGaD
Alprostadil—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000168	0.00031	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—PTPN11—peripheral nervous system neoplasm	0.000164	0.00214	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—KNG1—peripheral nervous system neoplasm	0.000161	0.0021	CbGpPWpGaD
Alprostadil—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.000297	CcSEcCtD
Alprostadil—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.000297	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000159	0.00206	CbGpPWpGaD
Alprostadil—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000158	0.000292	CcSEcCtD
Alprostadil—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000156	0.000288	CcSEcCtD
Alprostadil—PTGIR—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000155	0.00202	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000155	0.00202	CbGpPWpGaD
Alprostadil—ABCC4—Ectoderm Differentiation—MYC—peripheral nervous system neoplasm	0.000155	0.00202	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000155	0.00201	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000155	0.00201	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ENO2—peripheral nervous system neoplasm	0.000152	0.00197	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000152	0.00197	CbGpPWpGaD
Alprostadil—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000151	0.000278	CcSEcCtD
Alprostadil—PTGER1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.00015	0.00194	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.00015	0.00194	CbGpPWpGaD
Alprostadil—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.00027	CcSEcCtD
Alprostadil—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000146	0.000269	CcSEcCtD
Alprostadil—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.000266	CcSEcCtD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	0.000143	0.00187	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000143	0.00186	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000143	0.00186	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—GNAS—peripheral nervous system neoplasm	0.000141	0.00183	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.00014	0.00182	CbGpPWpGaD
Alprostadil—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000257	CcSEcCtD
Alprostadil—Rash—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000256	CcSEcCtD
Alprostadil—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000256	CcSEcCtD
Alprostadil—Headache—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000255	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000136	0.00177	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000136	0.00177	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000136	0.00177	CbGpPWpGaD
Alprostadil—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.000249	CcSEcCtD
Alprostadil—ABCC4—Hemostasis—HGF—peripheral nervous system neoplasm	0.000134	0.00175	CbGpPWpGaD
Alprostadil—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000242	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000129	0.00168	CbGpPWpGaD
Alprostadil—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000237	CcSEcCtD
Alprostadil—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000237	CcSEcCtD
Alprostadil—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000236	CcSEcCtD
Alprostadil—ABCC5—Metabolism—ENO2—peripheral nervous system neoplasm	0.000127	0.00165	CbGpPWpGaD
Alprostadil—ABCC5—Disease—SLC2A1—peripheral nervous system neoplasm	0.000122	0.00159	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000122	0.00159	CbGpPWpGaD
Alprostadil—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000223	CcSEcCtD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.00012	0.00156	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000119	0.00154	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—BCHE—peripheral nervous system neoplasm	0.000108	0.0014	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000107	0.00139	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000107	0.00139	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000103	0.00133	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—TH—peripheral nervous system neoplasm	0.000101	0.00131	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—NRAS—peripheral nervous system neoplasm	9.89e-05	0.00129	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PTPN11—peripheral nervous system neoplasm	9.8e-05	0.00127	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	9.44e-05	0.00123	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	9.44e-05	0.00123	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	9.18e-05	0.00119	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KNG1—peripheral nervous system neoplasm	9.18e-05	0.00119	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	8.74e-05	0.00114	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	8.74e-05	0.00114	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	8.4e-05	0.00109	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	8.25e-05	0.00107	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GNAS—peripheral nervous system neoplasm	8.25e-05	0.00107	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ABCB1—peripheral nervous system neoplasm	8.1e-05	0.00105	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GNAS—peripheral nervous system neoplasm	8.02e-05	0.00104	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	8.02e-05	0.00104	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TP53—peripheral nervous system neoplasm	7.56e-05	0.000983	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	7.39e-05	0.00096	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—HRAS—peripheral nervous system neoplasm	7.23e-05	0.00094	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTPN11—peripheral nervous system neoplasm	6.85e-05	0.00089	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.52e-05	0.000848	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—AKT1—peripheral nervous system neoplasm	6.39e-05	0.00083	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	6.15e-05	0.000799	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.98e-05	0.000777	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.92e-05	0.00077	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NRAS—peripheral nervous system neoplasm	5.89e-05	0.000766	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	5.68e-05	0.000738	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	5.68e-05	0.000738	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.58e-05	0.000725	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.58e-05	0.000725	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.43e-05	0.000706	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ERBB2—peripheral nervous system neoplasm	5.41e-05	0.000703	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.96e-05	0.000645	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.62e-05	0.000601	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TP53—peripheral nervous system neoplasm	4.51e-05	0.000586	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.41e-05	0.000573	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.41e-05	0.000573	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—HRAS—peripheral nervous system neoplasm	4.31e-05	0.000561	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.15e-05	0.00054	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.15e-05	0.00054	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NRAS—peripheral nervous system neoplasm	4.12e-05	0.000535	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.04e-05	0.000525	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.04e-05	0.000525	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4e-05	0.00052	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4e-05	0.00052	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MYC—peripheral nervous system neoplasm	3.83e-05	0.000499	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—AKT1—peripheral nervous system neoplasm	3.81e-05	0.000495	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.8e-05	0.000494	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	3.67e-05	0.000477	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	3.67e-05	0.000477	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.63e-05	0.000472	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.35e-05	0.000436	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.35e-05	0.000436	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.21e-05	0.000417	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.12e-05	0.000406	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.12e-05	0.000406	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HRAS—peripheral nervous system neoplasm	3.01e-05	0.000392	CbGpPWpGaD
Alprostadil—ABCC5—Disease—AKT1—peripheral nervous system neoplasm	2.66e-05	0.000346	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.56e-05	0.000333	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.56e-05	0.000333	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.45e-05	0.000319	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.45e-05	0.000319	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AKT1—peripheral nervous system neoplasm	2.23e-05	0.00029	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.17e-05	0.000282	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.17e-05	0.000282	CbGpPWpGaD
